Linked Life Data

19597027

Source:http://linkedlifedata.com/resource/pubmed/id/19597027

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
23
pubmed:dateCreated
2009-8-7
pubmed:abstractText
This phase II study evaluated efficacy and safety of single-agent axitinib, an oral, potent, selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2, and -3, in patients with advanced non-small-cell lung cancer (NSCLC).
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
1527-7755
pubmed:author
pubmed:issnType
Electronic
pubmed:day
10
pubmed:volume
27
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
3836-41
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.
pubmed:affiliation
University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390-8852, USA. joan.schiller@utsouthwestern.edu
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Clinical Trial, Phase II